Patients with extensive regional lymph node involvement (pN2) following potentially curative surgery for colorectal cancer are at increased risk for developing peritoneal metastases: a retrospective single-institution study

2018 ◽  
Vol 21 (3) ◽  
pp. 287-296 ◽  
Author(s):  
A. Bhatt ◽  
R. Bhamre ◽  
J. Rohila ◽  
V. Kalikar ◽  
A. Desouza ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Regional Lymph Node ◽  
Lymph Node Involvement ◽  
Peritoneal Metastases ◽  
Single Institution ◽  
Curative Surgery ◽  
Regional Lymph Node Involvement ◽  
Increased Risk ◽  
Node Involvement

scholarly journals Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy

Cancer ◽  
2003 ◽  
Vol 97 (10) ◽  
pp. 2425-2431 ◽  
Author(s):  
Igor Frank ◽  
John C. Cheville ◽  
Michael L. Blute ◽  
Christine M. Lohse ◽  
Ajay Nehra ◽  
...  
Keyword(s):  
Lymph Node ◽  
Urinary Bladder ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Regional Lymph Node ◽  
Transitional Cell ◽  
Lymph Node Involvement ◽  
Regional Lymph Node Involvement ◽  
Node Involvement

Regional lymph node involvement in benign renal angiomyolipoma

1984 ◽  
Vol 34 (4) ◽  
pp. 889-893
Author(s):  
Toshiaki Manabe ◽  
Yoshikazu Tasaka ◽  
Masamichi Amano ◽  
Takeshi Okunobo
Keyword(s):  
Lymph Node ◽  
Regional Lymph Node ◽  
Lymph Node Involvement ◽  
Renal Angiomyolipoma ◽  
Regional Lymph Node Involvement ◽  
Node Involvement

scholarly journals Prognosis vs Treatment Interaction

2018 ◽  
Vol 2 (1) ◽  
Author(s):  
Jack Cuzick
Keyword(s):  
Lymph Node ◽  
Poor Prognosis ◽  
Regional Lymph Node ◽  
Lymph Node Involvement ◽  
Clinical Markers ◽  
Relative Benefit ◽  
Regional Lymph Node Involvement ◽  
Absolute Benefit ◽  
Node Involvement ◽  
Treatment Interaction

Abstract There is a somewhat confused belief that a biomarker must show an interaction effect with a treatment before it can be used to determine the need for such a treatment. This is rarely true for well-established clinical markers such as tumor size or regional lymph node involvement. In many cases, this is also not true for biomarkers, especially when considering nontargeted therapies. Here I argue that for nontargeted treatments prognosis is often more important than interaction with treatment, because it is the absolute and not the relative benefit that matters, and when there is no treatment interaction, the same relative benefit translates into a larger absolute benefit for poor prognosis patients.

scholarly journals Regional Lymph Node Involvement Among Patients With De Novo Metastatic Breast Cancer

2020 ◽  
Vol 3 (10) ◽  
pp. e2018790
Author(s):  
Almir Bitencourt ◽  
Carolina Rossi Saccarelli ◽  
Elizabeth A. Morris ◽  
Jessica Flynn ◽  
Zhigang Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Lymph Node ◽  
De Novo ◽  
Regional Lymph Node ◽  
Metastatic Breast ◽  
Lymph Node Involvement ◽  
Regional Lymph Node Involvement ◽  
Node Involvement
Sign in / Sign up

Export Citation Format

Share Document